Fujirebio’s Lumipulse G NfL and Lumipulse G pTau 217 blood tests received Health Canada Class II medical device licenses for use in Canada. The approvals cover quantitative neurofilament light chain measurement for neuroaxonal injury and a plasma assay targeting Alzheimer-linked pTau 217 for differentiating neurodegeneration causes. Both assays were cleared for use on Fujirebio’s fully automated Lumipulse G immunoassay platform. The company said CE marking was granted earlier this year for each test, and the new Canadian licenses support broader adoption of blood-based biomarkers in clinical settings.